Online inquiry

IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15664MR)

This product GTTS-WQ15664MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4072
UniProt ID P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15664MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13285MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ2564MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ1843MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ5253MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ8479MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ10626MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ9070MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ1779MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW